FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.171,22 +1.892,26 (+3,30%)
Indaptus Therapeutics, Inc. (INDP)
Dopo ore:
| Chiusura precedente | 2,0300 |
| Aperto | 2,1063 |
| Denaro | 1,4400 x 200 |
| Lettera | 2,6200 x 200 |
| Min-Max giorno | 2,0100 - 2,1063 |
| Intervallo di 52 settimane | 1,5600 - 4,0800 |
| Volume | |
| Media Volume | 88.822 |
| Capitalizzazione | 17,249M |
| Beta (5 anni mensile) | 1,23 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,8300 |
| Prossima data utili | 03 mag 2024 - 07 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,00 |
GlobeNewswireIndaptus Therapeutics to Present at the LD Micro Main Event XVI
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVI. The conference is being held on October 3 – 5, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event: LD Micro Main Event XVIPresentation Date: Tuesday, October 3Time: 12:30pm PT (Track 3)Webcast Link: https://me23.sequireevents.com/ A live webcast of the presentation can
GlobeNewswireRegistration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023
Meet with Indaptus Therapeutics’ CEO Jeffrey Meckler Tribe Public Indaptus Event Tribe Public Indaptus Event NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus’ CEO, Jeffrey Meckler will present at Tribe Public’s Webinar Presentation and Q&A Event titled “Immunotherapy Reimagined." The Event is scheduled to begin at 8:30am pacific/11:30am eastern on Friday, September 29, 2023. To register to join the complimentary event, please visit t
- GlobeNewswire
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
Following evidence of marked pharmacodynamic activity in first cohort, Cohort 2 has dose reduced while anticipating a similar effectNEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial. This cohort dose is a dose reduction from the previous cohort based on the significant pharmacodynamic effect seen with
